Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (163)	6/19/2000 8:57:00 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 2243

From a cbsmarketwatch article: Incyte's rise was apparently fueled by general enthusiasm for genomics. There did not appear to be any extraordinary developments Monday at the company that propelled its shares higher. A company spokeswoman was not immediately available Monday for comment. Incyte specializes in selling access to its databases of genetic information. Pharmaceutical and biotechnology companies can use the genetic information in developing new disease treatments. Jim